Literature DB >> 20946952

Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold?

Kathryn A DeFea1.   

Abstract

Over the last decade β-arrestins have emerged as pleiotropic scaffold proteins, capable of mediating numerous diverse responses to multiple agonists. Most well characterized are the G-protein-coupled receptor (GPCR) stimulated β-arrestin signals, which are sometimes synergistic with, and sometimes independent of, heterotrimeric G-protein signals. β-arrestin signaling involves the recruitment of downstream signaling moieties to β-arrestins; in many cases specific sites of interaction between β-arrestins and the downstream target have been identified. As more information unfolds about the nature of β-arrestin scaffolding interactions, it is evident that these proteins are capable of adopting multiple conformations which in turn reveal a specific set of interacting domains. Recruitment of β-arrestin to a specific GPCR can promote formation of a specific subset of available β-arrestin scaffolds, allowing for a higher level of specificity to given agonists. This review discusses recent advances in β-arrestin signaling, discussing the molecular details of a subset of known β-arrestin scaffolds and the significance of specific binding interactions on the ultimate cellular response.
Copyright © 2010 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20946952     DOI: 10.1016/j.cellsig.2010.10.004

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  63 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

Review 2.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

Review 3.  GPCR mediated regulation of synaptic transmission.

Authors:  Katherine M Betke; Christopher A Wells; Heidi E Hamm
Journal:  Prog Neurobiol       Date:  2012-01-28       Impact factor: 11.685

4.  Arrestin(g) podocyte injury with endothelin antagonism.

Authors:  Roderick J Tan; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 10.121

5.  Differential regulation of somatostatin receptor dephosphorylation by β-arrestin1 and β-arrestin2.

Authors:  Andrea Kliewer; Stefan Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-26       Impact factor: 3.000

6.  Prolonged Morphine Treatment Alters Expression and Plasma Membrane Distribution of β-Adrenergic Receptors and Some Other Components of Their Signaling System in Rat Cerebral Cortex.

Authors:  Lucie Hejnova; Jitka Skrabalova; Jiri Novotny
Journal:  J Mol Neurosci       Date:  2017-10-28       Impact factor: 3.444

Review 7.  G-Protein-Coupled Receptor Signaling in Cilia.

Authors:  Kirk Mykytyn; Candice Askwith
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-09-01       Impact factor: 10.005

8.  Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Authors:  Laura C Sullivan; Teresa S Chavera; Raehannah J Jamshidi; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-22       Impact factor: 4.030

Review 9.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

Review 10.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.